Yes, most non-opioid analgesics such as acetaminophen and ibuprofen do not interact with selegiline. However, avoid combining Eldepryl with non-steroidal anti-inflammatory drugs that contain COX-2 inhibitors at high doses, as they may increase blood pressure.
If you experience a sudden rise in blood pressure, headaches, or a pounding heart, seek immediate medical attention. Mild increases may be managed by monitoring blood pressure and avoiding further tyramine sources.
Selegiline is primarily metabolized by the liver, and mild to moderate renal impairment does not typically require dose adjustment. Severe renal failure should be evaluated by a specialist.
Patients often report modest improvement within 2-4 weeks, with maximal benefit seen after several months of consistent therapy.
Weight loss has been reported in some individuals, likely related to increased metabolism and gastrointestinal side effects. If significant, discuss nutritional support with your clinician.
Both strengths contain the same inactive ingredients and have identical release characteristics; the only difference is the amount of selegiline per tablet.
For most elective surgeries, continuation is acceptable, but inform the surgical team of your MAO-B inhibitor use, especially if they plan to administer certain anesthetic agents.
Yes, but keep the medication in its original labeled container, carry a copy of the prescription, and be aware of local regulations concerning controlled substances.
Always consult your healthcare provider before changing brands, as tablet formulations and excipients may differ, potentially affecting tolerability.
Eldepryl (selegiline) is selective for MAO-B at therapeutic doses, whereas some other agents may inhibit both MAO-A and MAO-B, leading to a higher risk of dietary tyramine reactions.
Eldepryl is a brand-name medication that contains selegiline as its active ingredient. Selegiline is a selective monoamine oxidase-B (MAO-B) inhibitor used in the field of neurology. In Hong Kong, Eldepryl is available as a pill in strengths of 5 mg and 10 mg and is classified as a prescription-only drug.
Selegiline selectively blocks the enzyme monoamine oxidase-B. MAO-B normally breaks down dopamine in the brain. By inhibiting this enzyme, Eldepryl increases the amount of dopamine available in neuronal pathways, helping to alleviate the motor symptoms of Parkinson’s disease. The drug’s effects begin within a few days, reach a peak after several weeks, and are maintained as long as therapy continues. Selegiline is metabolized primarily in the liver to amphetamine-like metabolites, which contribute to its pharmacologic profile.
Evidence-Based Off-Label Uses Selegiline has been studied as an adjunct treatment for major depressive disorder and for neuroprotective strategies in Alzheimer’s disease. While clinical trials suggest potential benefit, these indications are not approved by regulatory agencies in Hong Kong.
Disclaimer: Off-label use requires medical supervision and individualized risk assessment.
Absolute Contraindications
Relative Contraindications
Special Populations
Standard dosing for Parkinson’s disease:
Initiate with 5 mg once daily, taken in the morning with or without food.
If additional symptom control is needed, the dose may be increased to 10 mg once daily after at least two weeks of stable dosing.
Off-label dosing for depression (only under specialist care):
May involve 10 mg taken twice daily; this regimen is not FDA/EMA-approved in Hong Kong.
Special population adjustments:
Elderly or patients with hepatic impairment often start at 5 mg and may remain at that dose.
Administration guidance:
Swallow the pill whole; do not crush or chew.
Store at room temperature, away from moisture and direct sunlight.
Missed dose:
Take the missed dose as soon as remembered if it is at least 6 hours before the next scheduled dose; otherwise skip it and resume the regular schedule. Do not double the dose.
Overdose:
Symptoms may include severe hypertension, agitation, and cardiac arrhythmias. Seek emergency medical care; supportive measures and blood pressure control are primary treatments.
Discontinuation:
Abrupt cessation is generally safe, but patients should discuss any plan to stop therapy with a healthcare professional to monitor for withdrawal or rebound symptoms.
This article provides educational information about Eldepryl and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
